Dolores Schendel, PhD

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed MDG1011 and Medigene’s future research and targets.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the phase 1/2 study evaluating MDG1011.